Ozmosi | Lacidipine Drug Profile

Product Description

Mechanisms of Action: Calcium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Hypertension|Type 2 Diabetes

Phase 3: Hypertension

Phase 2: Angina, Stable|Angina Pectoris

Phase 1: Healthy Volunteers

Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
CTR20251608	N/A	Completed	Hypertension	2025-06-13	2025-06-22	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20251609	N/A	Completed	Hypertension	2025-06-08	2025-06-22	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20250802	N/A	Completed	Hypertension	2025-05-29	2025-06-17	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20250915	N/A	Completed	Hypertension	2025-04-20	2025-06-08	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20244016	N/A	Completed	Hypertension	2025-01-22	2025-05-17	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20242977	N/A	Completed	Hypertension	2024-11-13	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20230126	N/A	Completed	Hypertension	2023-04-01	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20201801	N/A	Completed	Hypertension	2020-12-31	2025-04-29	Patient Enrollment\|Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20191645	N/A	Completed	Hypertension	2020-04-13	2025-04-29	Patient Enrollment\|Treatments
NCT02240641	N/A	Terminated	Hypertension	2000-09-01	2019-03-20	Treatments
NCT02235415	N/A	Completed	Hypertension	1999-09-01	2019-03-20
CTR20250803	N/A	Not yet recruiting	Hypertension	None	2025-04-29	Treatments\|Trial Status
CTR20232908	N/A	Not yet recruiting	Hypertension	None	2025-04-29	Patient Enrollment\|Treatments\|Trial Status
CTR20233788	N/A	Not yet recruiting	Hypertension	None	2025-04-29
NCT02264158	P1	Completed	Healthy Volunteers	2002-03-01	2019-03-20	Treatments
NCT02209649	P1	Completed	Healthy Volunteers	1999-12-01	2019-03-20	Treatments
NCT02203500	P1	Completed	Healthy Volunteers	1999-01-01	2019-03-20	Treatments
NCT02218684	P1	Completed	Healthy Volunteers	1998-11-01	2019-03-20	Treatments
NCT02232607	P2	Completed	Angina, Stable\|Angina Pectoris	1999-06-01	2019-03-20	Treatments
Lacidipine in Medical Practice	P3	Completed	Hypertension	1998-01-01	2019-03-20	Treatments
ELDER	P4	Completed	Hypertension	2009-07-01	2019-03-21	Treatments
NCT00338338	P4	Completed	Hypertension	2007-09-14	2019-03-21	Treatments
LAC103842	P4	Completed	Hypertension\|Type 2 Diabetes	2006-05-01	2019-03-21	Treatments
NCT02235402	P4	Completed	Hypertension	2000-03-01	2019-03-20	Treatments
NCT00533858	P4	Unknown status	Hypertension	None	2019-03-21	Treatments

Recent News Events

Date	Type	Title
04/25/2024	PubMed	Fabrication, optimization, and evaluation of lyophilized lacidipine-loaded fatty-based nanovesicles as orally fast disintegrating sponge delivery system.
04/10/2024	PubMed	Ternary solid dispersions of lacidipine: Enhancing dissolution and supersaturation maintenance through strategic formulation optimization.
03/01/2024	PubMed	Effects of adenosine triphosphate, Lacidipine, and Benidipine on 5-fluorouracil-induced kidney damage in rats.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Lacidipine

Alternative Names: lacidipine, motens Clinical Status: Inactive Latest Update: 2024-04-25 Latest Update Note: PubMed Publication